ACHNYSEWholesale-Medical, Dental & Hospital Equipment & SuppliesFiscal year ends December 31
ACCENDRA HEALTH INC/VA/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.22−0.01 (-6.30%)
Close on Oct 19, 2026
- Market cap
- $16.89M
- P/E (TTM)
- –
- Dividend yield
- –
ACCENDRA HEALTH INC/VA/ revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Direct | – | – | – | – | – | $673.88M | $695.02M | $686.85M | $660.40M | $637.84M | $664.43M | $648.28M | – | – |
| Products & Healthcare Services | – | – | – | – | – | $1.96B | $2.00B | $2.03B | $2.01B | $1.97B | $1.99B | $1.94B | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Direct | – | – | – | – | – | $60.14M | $69.56M | $79.93M | $64.79M | $45.88M | $77.51M | $64.44M | – |
| Products & Healthcare Services | – | – | – | – | – | $1.15M | $25.83M | $4.23M | $11.47M | $11.49M | $33.25M | $19.80M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes | $198.82M | $185.79M | $203.58M | $201.37M | $191.06M | $187.36M | $200.37M | $202.76M | $194.36M | – | – | – | 32.4% | +4.1% |
| Sleep therapy | $148.58M | $166.92M | $190.77M | $185.80M | $181.62M | $181.86M | $183.52M | $177.15M | $170.24M | – | – | – | 24.2% | -18.2% |
| Home respiratory therapy | $91.00M | $97.18M | $107.66M | $107.26M | $109.53M | $108.61M | $108.49M | $108.97M | $109.69M | – | – | – | 14.8% | -16.9% |
| Ostomy | $55.68M | $51.34M | $58.17M | $53.27M | $51.89M | $49.50M | $53.74M | $50.56M | $47.06M | – | – | – | 9.1% | +7.3% |
| Other | $47.68M | $57.37M | $71.53M | $72.59M | $72.30M | $71.77M | $69.62M | $68.19M | $66.26M | – | – | – | 7.8% | -34.1% |
| Wound care | $40.19M | $39.40M | $47.04M | $48.00M | $46.82M | $46.65M | $50.54M | $51.48M | $47.16M | – | – | – | 6.6% | -14.2% |
| Urology | $31.30M | $29.79M | $30.21M | $28.98M | $28.70M | $28.14M | $28.74M | $27.75M | $25.65M | – | – | – | 5.1% | +9.1% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | $2.58B | $2.64B | $2.66B | $2.61B | $2.55B | $2.59B | $2.52B | – | – |
| International | – | – | – | – | – | $51.33M | $59.22M | $59.66M | $62.00M | $62.07M | $67.90M | $72.79M | – | – |
From the segment and revenue-disaggregation notes of Accendra Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.